New methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and the use thereof in cancer vaccination are provided. The method includes introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).